Reversal of diabetes by the creation of neo-islet tissues into a subcutaneous site using islet cell sheets. 2011

Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
Department of Surgery, Fukushima Medical University, Fukushima, Japan.

BACKGROUND There remains a paucity of therapeutic approaches to completely treat diabetes mellitus. This study was designed to develop a dispersed islet cell-based tissue engineering approach to engineer functional neo-islet tissues in the absence of traditional bioabsorbable scaffold matrices. METHODS Specialized coated plastic dishes were prepared by covalently immobilizing a temperature-responsive polymer, poly(N-isopropylacrylamide), onto the plastic followed by coating with laminin-5. Dispersed rat islet cells were plated on the laminin-5-poly(N-isopropylacrylamide) dishes. After 2 days of culturing, islet cells were harvested as a uniformly connected tissue sheet by lowering the culture temperature from 37°C to 20°C for 30 min. Two harvested islet cell sheets were transplanted into the subcutaneous space of streptozotocin-induced diabetic severe combined immunodeficiency (SCID) mice to engineer neo-islet tissues in vivo. Therapeutic effects were investigated after the tissue engineering procedures. RESULTS In all of the diabetic SCID mice transplanted with the islet sheets, serum hyperglycemia was successfully reverted to a steady normoglycemic level. The recipient SCID mice demonstrated positive for serum rat C-peptide and elevated serum insulin levels. Moreover, the islet cell sheet-transplanted SCID mice demonstrated rapid glucose clearance and return of serum glucose levels after intraperitoneal glucose tolerance test. Histological examination revealed that the transplanted islet cell sheets were structured as flat clusters of islet tissues in which an active vascular network manifested within and surrounding the newly formed tissues. CONCLUSIONS This study describes a new proof-of-concept therapeutic approach to engineer functional neo-islet tissues for the treatment of type 1 diabetes mellitus.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
May 2006, Transplantation,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
June 1992, Transplantation proceedings,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
November 2011, Transplantation proceedings,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
August 1982, Diabetes,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
June 2011, Nature protocols,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
January 2002, Transplantation,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
March 2016, Nature protocols,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
July 2018, The Journal of surgical research,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
August 2012, Biochemical and biophysical research communications,
Takahiro Saito, and Kazuo Ohashi, and Rie Utoh, and Hirofumi Shimizu, and Kazuya Ise, and Hiroyuki Suzuki, and Masayuki Yamato, and Teruo Okano, and Mitsukazu Gotoh
September 1981, Science (New York, N.Y.),
Copied contents to your clipboard!